Biofrontera (BFRI) Cash from Financing Activities (2020 - 2025)
Biofrontera (BFRI) posted quarterly Cash from Financing Activities of $2.4 million for Q4 2025, down 41.98% year-over-year from $4.0 million in Q4 2024, and down 41.98% quarter-over-quarter from $4.0 million in Q4 2024.
Biofrontera (BFRI) Cash from Financing Activities (2020 - 2025) Analysis & Trends
Biofrontera's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $2.4 million for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 41.98% year-over-year to $2.4 million; the TTM figure through Dec 2025 stood at $6.1 million (down 58.87% YoY), while the FY2025 annual figure was $10.8 million, down 26.86% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $2.4 million, down from $4.0 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $43.8 million in Q4 2021, with the low at -$298000.0 in Q3 2024.
- The 5-year median for Cash from Financing Activities is $4.3 million (2022), against an average of $7.3 million.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 3926.45% in 2022, then tumbled 150.42% in 2024.
- Biofrontera's Cash from Financing Activities stood at $43.8 million in 2021, then sank by 89.44% to $4.6 million in 2022, then jumped by 45.01% to $6.7 million in 2023, then tumbled by 39.68% to $4.0 million in 2024, then slumped by 41.98% to $2.4 million in 2025.
- Business Quant data shows BFRI's Cash from Financing Activities at $2.4 million in Q4 2025, $4.0 million in Q4 2024, and -$298000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Biofrontera | 19.06 Mn | 14.35 Mn | 9.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Dec 31, 2024 | 4.05 Mn |
| Sep 30, 2024 | -298,000.00 |
| Sep 30, 2024 | -298,000.00 |
| Jun 30, 2024 | 5.28 Mn |
| Jun 30, 2024 | 5.28 Mn |
| Mar 31, 2024 | 5.80 Mn |
| Mar 31, 2024 | 5.80 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Dec 31, 2023 | 6.71 Mn |
| Sep 30, 2023 | 591,000.00 |
| Sep 30, 2023 | 591,000.00 |
| Sep 30, 2022 | 4.63 Mn |
| Sep 30, 2022 | 4.63 Mn |
| Dec 31, 2021 | 43.83 Mn |
| Dec 31, 2021 | 43.83 Mn |
| Sep 30, 2021 | -121,000.00 |
| Sep 30, 2021 | -121,000.00 |